INTRODUCTION
Obesity and its comorbidities pose a growing therapeutic challenge (Wang et al., 2011) . White adipose tissue (WAT) is the main ''storage site'' of excess energy, primarily in the form of triglycerides. In addition, a functionally and morphologically distinct adipocyte subset-whose dense mitochondrial, innervation, and vascular content earned it the moniker of ''brown'' adipose tissue (BAT)-dissipates energy as heat (nonshivering thermogenesis). Brown adipocytes uncouple mitochondrial electron transport from ATP synthesis to a greater extent than other cells by permeabilizing the inner mitochondrial membrane to allow inter-membrane proton to leak back into the mitochondrial matrix, primarily through uncoupling protein-1 (Ucp1), but also through other mitochondrial proteins (Ravussin and Galgani, 2011) . Promoting BAT function has therapeutic potential to combat obesity (Farmer, 2009) . But its limited amount and activity in humans are unlikely to offset the positive energy balance associated with excessive WAT deposition (Virtanen and Nuutila, 2011) .
As an alternative strategy to increase energy expenditure and prevent weight gain, we investigated mechanisms that confer BAT-like features onto WAT, thus remodeling the latter from an energy storage into an energy-disposal site (Kozak, 2010) . The metabolic benefits of this conversion include prevention of diet-induced obesity and increased insulin sensitivity (Seale et al., 2011) . Browning of rodent WAT can be brought about by hormones and cytokines, such as Irisin (Boströ m et al., 2012) and Fgf21 (Fisher et al., 2012) , as well as by transcriptional modulation through Prdm16 (Seale et al., 2011 ), FoxC2 (Cederberg et al., 2001 ), RIP140 (Powelka et al., 2006) , 4E-BP1 (Tsukiyama-Kohara et al., 2001 ), TIF2 (Picard et al., 2002) , pRb and p107 (Scimè et al., 2005) . However, there is an unmet need for strategies that would translate these mechanisms into the clinic.
Activation of the nuclear receptor Pparg by thiazolidinediones (TZDs) can also induce a brown-like phenotype in white adipocytes by promoting expression of brown adipocyte-specific genes (brown genes) and suppressing visceral WAT genes (white genes) (Vernochet et al., 2009 ). The mechanism of this ''browning'' effect is unclear, and is unlikely to be clinically applicable without further modulation, in view of the adverse effects associated with TZD use .
Activation of the NAD + -dependent deacetylase SirT1 by small molecules, calorie restriction or exercise promotes mitochondrial biogenesis and activities (Cantó et al., 2009; Milne et al., 2007) , raising the possibility that SirT1 regulates BAT functions. Furthermore, SirT1 gain-of-function mimics the insulin-sensitizing function of Pparg ligands in vivo (Banks et al., 2008) . In view of these facts, we asked whether the browning activity of Pparg is mediated through its SirT1-dependent deacetylation and whether SirT1 is also capable of inducing browning of WAT, similar to TZDs. We report that SirT1-dependent Pparg deacetylation promotes browning of subcutaneous WAT by regulating ligand-dependent coactivator/corepressor exchange at the Pparg transcriptional complex. We propose that SirT1-dependent Pparg deacetylation regulates energy homeostasis, promoting energy expenditure over energy storage.
RESULTS

SirT1 Deacetylates Pparg in a Ligand-Dependent Manner
We investigated whether Pparg activation by TZD ligands affects its acetylation. Indeed, treatment with rosiglitazone dose-dependently decreased Pparg acetylation ( Figure 1A ). Moreover, Pparg agonists facilitated, while the antagonist GW9662 prevented the interaction between Pparg and SirT1 ( Figures 1A and 1B) . Pparg acetylation was augmented by acetyltransferase Cbp ( Figure 1C) Figure S1 .
reveal that SirT1 deacetylates Pparg. Unlike other SirT1 substrates, Pparg requires agonist binding to engage SirT1 in vivo. Next we asked whether SirT1 interacts with Pparg in physiologic conditions. Accordingly, we detected SirT1 in Pparg immunoprecipitates from epididymal and inguinal WAT (eWAT and iWAT) lysates ( Figure 1F ). Taking advantage of Flag-tagged SirT1 in SirT1 Bacterial Artificial Chromosome Overexpressor transgenic mice (SirBACO) (Banks et al., 2008) , we demonstrated that Pparg could be detected by in vivo coimmunoprecipitation of Flag-SirT1 in iWAT ( Figure 1G ).
SirT1 Mimics the Effects of Pparg Ligands on White and Brown Genes
Since both TZDs and SirT1 decrease Pparg acetylation, we hypothesized that SirT1 gain-of-function phenocopies aspects of Pparg activation by TZDs. A known function of TZDs is to repress visceral WAT genes whose induction is generally associated with insulin resistance (Vernochet et al., 2009 ). Activation of SirT1 by resveratrol in 3T3-L1 white adipocytes had a similar effect (Figure 2A ). Overexpression of SirT1 did not affect adipogenesis ( Figures S2A-S2C ), but selectively decreased representative white genes Angiotensinogen (Agt), Resistin, Wdnm1L, Chemerin, and Pank3. The catalytically inactive SirT1 mutant, H363Y, was unable to repress most white genes (Figure 2B) . The inhibitory effect of SirT1 on these white genes is consistent with its lipid mobilizing function in white adipocyte (Picard et al., 2004) . Next we compared the effects of SirT1 with those of Pparg agonists on brown genes in HIB-1B cells (Tontonoz et al., 1994) . We chose these cells because their expression levels of Ucp1, SirT1 and its native inhibitor Deleted in breast cancer-1 (Dbc1) (Kim et al., 2008; Zhao et al., 2008) are more similar to subcutaneous WAT (iWAT) than those of 3T3-L1 white adipocytes ( Figure S2D ). Activating SirT1 with resveratrol (Lagouge et al., 2006) or Pparg with troglitazone increased Ucp1 while the SirT1 inhibitor nicotinamide mimicked the Pparg antagonist GW9662 to repress it ( Figure 2C ). Overexpression of WT or H363Y mutant SirT1 did not inhibit cellular differentiation ( Figure S2E ), but WT SirT1 decreased Pparg acetylation and increased BAT markers Ucp1 and Dio2, while the H363Y mutant had the opposite effect ( Figures 2D and 2E ). These data indicate that SirT1 deacetylase activity is required to promote brown gene expression and repress white genes in a cell-autonomous manner that mimics liganded Pparg.
SirT1 Induces ''Browning'' of Subcutaneous WAT In vivo, we observed a positive correlation of SirT1 levels with brown gene expression in different mouse adipose tissues; conversely, we observed a negative correlation of the SirT1 inhibitor Dbc1 with brown genes ( Figures 3A and S3A ). Based on these findings, we probed the browning function of SirT1 in vivo by using three mouse models of altered SirT1 activity: Sirt1 knockout mice (Sirt1 (Escande et al., 2010) and mice overexpressing SirT1 (SirBACO) (Banks et al., 2008) . In rare Sirt1 À/À mice that survived to adulthood (McBurney et al., 2003) , we saw normal levels of brown markers Ucp1 and C/ebpb in BAT ( Figure S3B ), but lower levels in iWAT ( Figure 3B ), indicating that SirT1 is required to maximize the thermogenic capacity of subcutaneous WAT.
To validate our finding, we surveyed adipose tissues in Dbc1 À/À mice after triggering thermogenesis by overnight cold exposure (4 C). We saw increased numbers of Ucp1-immunoreactive paucilocular iWAT adipocytes, which are usually unilocular ( Figure 3C ), together with increased expression of brown genes Ucp1 and C/ebpb, and suppression of white genes, Chemerin and Resistin ( Figures 3D and 3F ), suggestive of a ''browning'' of subcutaneous white adipocytes. In contrast, knockout of Dbc1 had no effect on Ucp1 expression in BAT ( Figures S3C and S3D ). We observed a similar Figure S3E ) but, unlike in subcutaneous iWAT, we saw no paucilocular adipocytes ( Figure 3C ). Owing to the extremely low levels of Ucp1 in eWAT ( Figures 3A and S3A ), it's unlikely that its induction in this tissue contributes significantly to overall thermogenesis, consistent with the observation that iWAT is Figure S4A . In (A) *p < 0.05, **p < 0.01 for Dbc1 À/À versus WT before cold exposure; #p < 0.05, ##p < 0.01
for Dbc1 À/À versus cold-exposed Dbc1 À/À mice. In (B) *p < 0.05. (n = 6-7).
(C and D) Ucp1 immunohistochemistry, H&E staining (C), and gene expression (D) in iWAT of 9-week-old male SirBACO mice after chronic cold exposure. *p < 0.05, **p < 0.01 versus WT (n = 6).
the WAT depot most prone to browning (Kozak, 2010) . If the browning effect associated with Dbc1 knockout was mediated by increased SirT1 activity, it should be phenocopied by SirT1 gain-of-function in SirBACO mice. Indeed, cold-exposed SirBACO mice had an increased number of Ucp1-immunoreactive paucilocular adipocytes in iWAT, as did Dbc1 À/À mice (Figure 3C ). The expression of brown markers, including Ucp1, Dio2, and C/ebpb was increased in iWAT of SirBACO mice ( Figures 3E and 3G ). Similar to Sirt1 À/À and Dbc1 À/À mice, SirBACO mice had only marginally enhanced expression of Ucp1 and C/ebpb in BAT ( Figures S3F and S3G ). Interestingly, Cbp-deficient mice-which are known to be insulin-sensitiveshow similar browning phenotypes (Yamauchi et al., 2002) . These data indicate a browning function of SirT1 in iWAT, rather than BAT.
SirT1 Gain-of-Function and Pparg Ligands Have Overlapping Insulin-Sensitizing Effects
We next investigated the metabolic correlates of our findings. Aging Dbc1 À/À mice become glucose intolerant without body weight changes (Figures 4A and S4A) . We exploited this feature to critically test the hypothesis that promoting BAT-like features in WAT benefits insulin sensitivity. We exposed insulin-resistant Dbc1 À/À mice and controls to 12 C, a moderately low temperature. Unlike acute cold exposure to 4 C, this treatment did not result in loss of body weight ( Figure S4A ). The 4-week treatment had no effect in controls, but restored glucose tolerance in Dbc1 À/À mice (Figures 4A and 4B), with increased expression of brown genes in iWAT (data not shown). In SirBACO mice, chronic cold exposure resulted in lesser weight gain ( Figure S4B ), despite increased food intake ( Figure S4C ), suggesting increased energy expenditure. Similar to acute cold exposure, we observed changes in iWAT, but not in BAT and eWAT (Figures S4D and S4E) , associated with the appearance of smaller, paucilocular or multilocular adipocytes with more intense Ucp1 immunoreactivity ( Figure 4C ). Gene expression studies demonstrated elevated levels of brown (Ucp1, Cox7a1, and Cidea), angiogenic (Vegf), and lipolytic genes (Atgl) (Figure 4D )-all indicative of improved WAT function along with brown remodeling. WAT ''insulin-resistance'' genes were concordantly decreased in iWAT from SirBACO mice on high-fat diet (HFD) ( Figure 4E ), similar to their downregulation by Pparg agonist (Vernochet et al., 2009) . As expected, Pparg acetylation was decreased in SirBACO mice ( Figure 4F ), presumably mirroring TZD's in vitro effect. If TZDs and SirT1-dependent Pparg deacetylation promoted browning through a shared molecular mechanism, we would expect that the in vivo effects of TZDs would be partly offset by SirT1 gain-of-function, to the extent that they are both mediated by browning of adipose tissue. This hypothesis can only be tested indirectly, as the systemic effects of SirT1 and TZDs on insulin sensitivity are not limited to browning of WAT, nor are they exclusively mediated by one another (i.e., there are SirT1-independent effects of TZDs and vice versa). Nonetheless, we investigated the ability of rosiglitazone to restore glucose tolerance in SirBACO and Dbc1 À/À mice rendered insulin-resistant with high-fat feeding. Indeed, administration of rosiglitazone improved glucose tolerance in high-fat-fed WT mice, but had only partial, statistically nonsignificant effects in either SirBACO ( Figures 4G, 4H , and S4F) or Dbc1 À/À mice ( Figures 4I, 4J , and S4G). These findings provide additional evidence for our hypothesis.
SirT1 Deacetylates Pparg on Lys268 and Lys293
We sought to identify SirT1-dependent deacetylation sites in Pparg. We used HPLC/MS/MS analysis on trypsin-and chymotrypsin-digested peptides to identify five acetylated lysines at residues 98, 107, 218, 268, and 293, with $87% coverage of Pparg sequence ( Figures S5A and S5B ). Among them, two evolutionally conserved residues in the helix 2-helix 2 0 region, Lys268 and Lys293 ( Figure S5C ), were deacetylated following rosiglitazone treatment (Figures 5A and 5B), suggesting that they are SirT1 substrates. In the Pparg tertiary structure (Figure S5D ), Lys268 juts out from the groove containing Ser273 (Lin et al., 2009; Nolte et al., 1998) , a cyclin-dependent kinase 5 (CDK5) phosphorylation site (Choi et al., 2010) , while Lys293 lies as a potential gatekeeper with its side chain facing Ser273. The loop following the Pparg helix 2 0 is highly flexible, and responds with different conformational changes to Pparg ligands with distinct transcriptional signatures (Waku et al., 2009) . Ligand binding induces a conformational change that hinders access to the groove, burying Lys293 (Figures 5C and S5E) . It bears to reason that this event may require debulking acetylated Lys293 through deacetylation. Unlike Lys293, Lys291 anchors on the opposite side of helix 2 0 , and upon ligand binding its long side chain abuts on the outside of the groove ( Figures S5D and S5E) . Consistently, mass spectroscopy analysis of Pparg peptides showed that it is not acetylated (data not shown).
Humans carrying the Pparg mutation P467L (Pro495 of murine Pparg2) are severely insulin-resistant and diabetic (Barroso et al., 1999) . This amino acid change disrupts a conserved coactivator-binding motif LxxLL (murine Pparg's amino acids 493-497) in helix 12 ( Figure S5F ). Interestingly, SirT1 interacts with another transcription factor, FoxO1, through the latter's cognate LxxLL motif (Nakae et al., 2006) . Thus, we asked whether the P467L mutation interferes with Pparg binding to and deacetylation by SirT1. Protein interaction modeling localized binding of (E and F) Expression of white genes (E) and Pparg acetylation (F) in iWAT of male SirBACO mice after 8 weeks on HFD. Mice were placed on HFD at 6 weeks of age. *p < 0.05, **p < 0.01 versus WT (n = 5). IP, Immunoprecipitation; IB, immunoblot. (G and H) IPGTT (G) and AUC (H) in male SirBACO mice fed with HFD for 6 weeks (starting at 12 weeks of age), and treated with rosiglitazone (rsg) or vehicle (veh) for 1 week. Body weight information is in Figure S4F . *p < 0.05, **p < 0.01 WT-rsg versus WT-veh (n = 6-8).
(I and J) IPGTTs (I) and AUC (J) in male Dbc1 À/À mice fed with HFD for 25 weeks before and after 1 week rosiglitazone (rsg) administration. Mice were placed on HFD at 5 weeks of age. Body weight information is in Figure S4G . *p < 0.05, **p < 0.01 for WT versus WT-rsg (n = 7). Values are presented as means ± SEM. See also Figure S4 . SirT1 to ligand-bound Pparg within the LxxLL motif ( Figure S5G ). Indeed, P467L Pparg was hyperacetylated, and showed reduced binding to SirT1 that failed to be rescued by SirT1 overexpression ( Figure 5D ). Alanine mutations of the LxxLL motif (L496A/L497A) also abolished the interaction of Pparg and SirT1 ( Figure 5E ). Mutating Lys293 or Lys268 in the hyperacetylated Pparg mutant P467L dramatically decreased its acetylation, providing further evidence that both residues are sites of Pparg acetylation ( Figure 5F ). Of interest, Pro495 (Pro467 in human) and Lys293 are juxtaposed by a bridge between Ile295 and His494 and the aromatic side chain of Phe315 in response to ligand binding (Waku et al., 2009 ). This conformation should facilitate SirT1 binding to the LxxLL motif, providing ready access to its substrates, Lys293 and the nearby Lys268.
Physiologic Regulation of Pparg Acetylation
To evaluate the significance of Pparg acetylation, we investigated its regulation by physiological cues. Pparg acetylation decreased in iWAT when brown genes were activated by cold exposure ( Figure 5G ), while it increased with insulin resistance brought about by HFD ( Figure 5G ). The increase of Pparg acetylation following HFD was associated with reduced interaction with SirT1 ( Figure 5H ) and was reversed by rosiglitazone administration ( Figure 5I ), Dbc1 knockout ( Figure 5J ) or SirT1 overexpression ( Figure 4F ). Moreover, activation of SIRT1 by resveratrol decreased PPARg acetylation in human subcutaneous adipose tissue ( Figure 5K ), in agreement with the insulin-sensitizing effects of resveratrol in humans (Timmers et al., 2011) . Total Pparg acetylation changed relatively little in vivo, consistent with the mass spectrometry demonstration that only two of five lysine residues are responsive to rosiglitazone ( Figure S5B ).
BAT-like Functions of Pparg Acetylation Site Mutants
We investigated the effects of Pparg deacetylation in adipocytes by generating stable clones of Swiss-3T3 fibroblasts expressing WT Pparg, or acetylation-mimetic K293Q (KQ), deacetylation-mimetic K293R (KR) and K268R/K293R (2KR) Pparg mutants. WT Pparg induced differentiation of Swiss 3T3 fibroblasts into adipocytes, as did KR, whereas KQ delayed it ( Figures 6A and S6A) . Strikingly, the 2KR mutant was more potent than WT Pparg in promoting lipid accumulation, increasing expression of the insulin-sensitizing adipokine, adiponectin, and promoting degradation of anti-adipogenic b-catenin (Liu et al., 2006) (Figures 6A and S6A ). These data indicate that deacetylation is required for full Pparg activation. Mitochondrial activity, as assessed by membrane potential, was inhibited by KQ, but enhanced by 2KR ( Figure 6C ). These findings were unrelated to mitochondrial biogenesis, assessed by measuring mitochondrial mass ( Figure 6C ), mitochondrial DNA, or mitochondrial protein content ( Figures S6C and S6D ).
2KR was more potent than WT to activate BAT genes including Ucp1, Elovl3, Cidea, Cox7a1, and Pgc1a ( Figures 6D and S6E ). In contrast, KQ selectively repressed expression of BAT genes and induced expression of white genes without affecting canonical Pparg targets ( Figures 6D, 6E , S6E, and S6F). Consistent with the induction of BAT genes, basal mitochondrial respiration and maximal mitochondrial respiratory capacity increased in cells expressing 2KR, as did oligomycin-dependent (i.e., ATP synthesis inhibition-dependent) proton leak (Figure 6B) . Another TZD-responsive gene, Fgf21 (Wang et al., 2008) , was likewise repressed by KQ and activated by 2KR (Figure 6D) . In summary, these data indicate that SirT1-dependent deacetylation of Pparg Lys268 and Lys293 mediates TZDinduced browning of white adipocytes, enhancing expression of characteristic BAT genes and repressing white ''insulin resistance'' genes.
SirT1-Dependent Deacetylation Modulates Pparg
Coactivator/Corepressor Exchange Ser273 phosphorylation regulates Pparg activity (Choi et al., 2010) . Interestingly, Ser273 phosphorylation parallels acetylation of Lys293, but not of Lys268 ( Figures S7A and S7B ). Thus, we investigated whether the transcriptional selectivity and metabolic functions of Pparg deacetylation are mediated through ligand-dependent Ser273 dephosphorylation. Dephosphorylation of Ser273 by TZD is required to induce adiponectin (Choi et al., 2010) . In Swiss 3T3 cells, stable overexpression of Pparg S273A (SA) or S273A/2KR (AR) mutants resulted in overlapping effects on adiponectin ( Figure S7C ). In contrast, the AR mutant trumped the effect of the SA mutant by activating brown genes ( Figure S7D ). These data indicate that Pparg acetylation and Ser273 phosphorylation coordinately promote adipokine production, while deacetylation is the main signal affecting brown gene expression. Ligand binding induces Pparg/Rxr dimerization and cofactor exchange. We hypothesized that Pparg deacetylation might dial in specificity of brown gene expression through coactivator/corepressor recruitment. Prdm16 is a determinant of the brown adipocyte lineage (Seale et al., 2008) that has been shown to induce browning of subcutaneous WAT (Seale et al., 2011) . We observed that Prdm16 binding to Pparg was dependent on rosiglitazone ( Figure 7A, lanes 1-2) . Pparg acetylation by Cbp prevented Prdm16 binding, but rosiglitazone was able to partly relieve the inhibition to an extent that was commensurate with Pparg deacetylation ( Figure 7A, lanes 3-4) . Accordingly acetylation-defective Pparg 2KR showed constitutive, ligand-independent binding to Prdm16 ( Figure 7B ). Likewise, Cbp blocked the Pparg/Prdm16 interaction while SirT1 overexpression was able to rescue it ( Figure 7C ), supporting a key role of deacetylation in this process. SirT1 gain-of-function mimicked the effect of Pparg ligand to promote Prdm16 binding while the Pparg (J) Pparg acetylation in response to TZD and deletion of Dbc1. Chow-fed male WT mice were treated with rosiglitazone for 3 days. Twelve milligrams of protein from pooled iWAT of four mice was used for IP with Pparg antibody (H100). (K) PPARg acetylation in human adipose tissue in response to resveratrol. Human subcutaneous adipose fragments were treated with resveratrol (50 mM) for 12 hr; 1.2 mg protein was immunoprecipitated with PPARg antibody (H100). We estimated relative levels of PPARg acetylation (Ac-Pparg) using densitometry with NIH ImageJ software. See also Figure S5. antagonist GW9662 blocked the effect of SirT1 ( Figure 7D ). In addition, we demonstrated that Pparg could be detected in chromatin immunoprecipitates from the Ucp1 enhancer (Chen et al., 2009) together with Prdm16 in HIB-1B cells expressing SirT1, but not its HY mutant ( Figure 7E ). In contrast, neither in vivo nor in vitro did we detect any interaction between Prdm16 and SirT1 (data not shown).
Site-directed mutagenesis of individual lysine residues demonstrated that Lys293, but not Lys268, was critical to recruit Prdm16 to Pparg ( Figure 7F ). Transcriptional corepressor NCoR is an important component of the Pparg complex. Thus, we investigated whether acetylation of these two lysines affected NCoR binding. Intriguingly, mutating either lysine to arginine abolished the interaction of NCoR with Pparg, suggesting that acetylation of both residues is required for this interaction ( Figure 7F ). Consistent with these data, Cbp increased NCoR binding to Pparg, while SirT1 prevented it (Figure 7G) . Therefore, deacetylation of Pparg on Lys293 is required to recruit coactivator Prdm16, while deacetylation on Lys268 and Lys293 is required to clear corepressor NCoR. These data indicate that the acetylation state of Lys268 and Lys293 is critical for corepressor/coactivator exchange.
DISCUSSION
This study illustrates that SirT1 gain-offunction induces BAT-like remodeling of white adipocytes in vivo and in vitro by deacetylating Pparg on Lys293 and Lys268. We identify SirT1 as a Pparg deacetylase, whose effects mimic biochemical, cell biological, and physiological outcomes of ligand-dependent Pparg activation. Mechanistically, this process is associated with recruitment of the brown cofactor Prdm16 and clearance of the corepressor NCoR from the Pparg complex. We propose a model in which the metabolic benefits of SirT1, the browning function of Pparg ligands and their ability to selectively recruit coactivator Prdm16 are subsumed under the unifying mechanism of Pparg deacetylation ( Figure 7H ). SirT1 is activated by energy deficiency (Cohen et al., 2004) and deacetylates Pparg at Lys268 and Lys293. Thus, we suggest that Pparg acetylation on Lys268 and Lys293 is a signal of plenty, as it favors lipid storage and cell proliferation ( Figure S6B) . Conversely, deacetylation of (H) Model of SirT1-dependent Pparg deacetylation in energy homeostasis and insulin sensitivity. When nutrients are available, SirT1 is inactive and Pparg is acetylated on Lys268 and Lys293. This condition favors lipid storage. During energy deprivation, SirT1 becomes active and is recruited to Pparg, possibly as a result of ligand-induced conformational changes, to deacetylate Lys268 and Lys293. In white adipocytes, the deacetylated Pparg interacts with Prdm16 to promote thermogenesis (energy expenditure) and improve insulin sensitivity. See also Figure S7 .
Pparg tilts the balance from energy storage to energy expenditure (thermogenesis) and promotes insulin sensitivity.
Pparg Deacetylation in Browning WAT
Promoting brown features in white adipocytes can prevent obesity and diabetes (Farmer, 2009) . In the present study, we propose a mechanism by which SirT1-mediated Pparg deacetylation might contribute to this process. The browning function of SirT1 in WAT should be distinguished from its role in BAT since we did not detect any effect of SirT1 gain-or loss-of-function in BAT in our mouse models. From a therapeutic standpoint, this is consistent with the idea that BAT itself plays a modest role in protecting from diet-induced weight gain, whereas converting WAT into a less efficient energy storage site might. It also suggests that browning of WAT occurs in a mechanistically distinct fashion from BAT activation. Indeed, several factors that promote WAT browning, such as Irisin (Boströ m et al., 2012) , Fgf21 (Fisher et al., 2012) , and Prdm16 (Seale et al., 2011) do so independently of BAT.
Unlike the browning factors mentioned above, SirT1 does not constitutively induce brown genes in iWAT at ambient temperature (data not shown), suggesting that hormonal or environmental cues-such as cold exposure-are required to activate SirT1-dependent mechanisms of iWAT browning. Pparg acetylation on Lys268 and Lys293 could therefore be exploited as readout to identify factors that modulate the browning process. The ability to regulate browning of WAT should be viewed as an essential component of any therapeutic approach that leverages this mechanism, since ''browned'' cells are energy inefficient, and might have undesired effects if left unchecked.
The SirT1-dependent browning process occurs in a heterogeneous fashion within morphologically and anatomically homogeneous adipose depots. This might be related to sympathetic innervation, a key modulator of BAT and Ucp1 induction in WAT (Bartness et al., 2010) . Or it is possible that the ability to activate the brown program in response to Pparg ligand or SirT1 gain-of-function is limited to a specialized subset of adipocytes. Alternatively, since vascular endothelial cells have pluripotent potential and can differentiate into pre-adipocytes (Tran et al., 2012) , activation of SirT1 and Pparg deacetylation could favor pre-adipocyte differentiation into brown (or ''brite'') adipocytes. This possibility is unlikely to account for brown gene induction in WAT following acute cold exposure, but might underlie the chronic effect of cold exposure.
Integrating Acetylation with Other Posttranslational Modalities of Pparg Regulation
Lysine residues can be modified by sumoylation and ubiquitination. Fgf21 (Dutchak et al., 2012) and TZDs (Pascual et al., 2005) are insulin-sensitizers with browning properties (Fisher et al., 2012; Vernochet et al., 2009 ) that promote Pparg sumoylation. The Fgf21-dependent sumoylation site on Pparg, Lys107 (Dutchak et al., 2012) , is strongly acetylated in our mass spectrometry analysis, but its acetylation is unaffected by rosiglitazone. It will be of interest to determine whether there exists a reciprocal regulation of acetylation and sumoylation at this site during the browning process. Ligand activation of Pparg increases its ubiquitin-mediated degradation (Hauser et al., 2000) , a process that could also be regulated by deacetylation of Lys268 and Lys293, because we observed that mutation of these two residues increased Pparg stability (data not shown).
TZDs inhibit CDK5-dependent phosphorylation of Pparg Ser273 (Choi et al., 2010) , a residue buried within the groove lined by Lys268 and Lys293. Consistent with prior results in different systems (Qiang et al., 2010 (Qiang et al., , 2011 , we show that Ser273 phosphorylation correlates with Lys293 acetylation, suggesting that the acetylation state of these two residues affects access of related kinases or phosphatases, to the phosphorylation site. We also found that the effects of acetylation and phosphorylation of these residues on brown gene expression diverge, while those on the regulation of adiponectin overlap. Therefore, acetylation of Pparg regulates its phosphorylation-mediated function. In summary, acetylation might integrate energy status with ligand availability to regulate protein stability and the effects of sumoylation and phosphorylation on Pparg activity.
Therapeutic Implications
Following the introduction of biguanides in the clinical management of diabetes in the 1940s, TZDs represent the only addition to the pharmacopeia of insulin-sensitizers. But their use has been tainted by liver toxicity, adverse effects on fluid balance, body weight, bone turnover, and certain types of cancer, as well as lingering if elusive links to cardiovascular risk (Rosen, 2010) . In addition, the TZD saga has negatively affected development of transcription factor-based therapeutics, even as recognition of their homeostatic role has grown exponentially . Our data do not amount to a rehabilitation of TZDs for treatment of metabolic disorders, but raise the interesting possibility that, by judicious use of SirT1 agonists in combination with appropriate Pparg ligands, it is possible to render WAT less efficient, thus warding off the adverse effects of TZD and paving the way for a reevaluation of Pparg as a therapeutic target (Qiang and Accili, 2012) . The Columbia University Animal Care and Utilization Committee approved all procedures. The high-fat diet contained 60% calories from fat, 20% from protein, and 20% from carbohydrates (Research Diet, D12492). For acute cold exposure, we placed animals at 4 C for 16 hr, and for chronic cold exposure we placed animals at 12 C on a 12-hr light/diet cycle for 4 weeks.
We injected rosiglitazone intraperitoneally (i.p.) daily at a dose of 10 mg/kg body weight, performed IPGTT as described (Banks et al., 2008) , and determined body compositions by NMR (Bruker Optics).
Plasmids and Cell Culture
We obtained pcDNA-Flag-Pparg2 (# 8895), pBabe-puro-Flag-HA-Pparg2 (# 8859) and pcDNA-Prdm16 (#15503) from Addgene, and generated Pparg mutants K293R, K293Q, K268R, K268Q, 2KR (K268R/K293R), P467L, P467L/K293R and P467L/K268Q, S273A, S273A/K268R/K293R (AR), and L496A/L497A (2LA) by site-directed mutagenesis. In this study, Pparg refers to the longer isoform Pparg2. We subcloned WT and H363Y mutant SirT1 cDNA into the BamHI site of pEGFP-N1 to generate N-terminal FLAG-and C-terminal GFP-tagged SirT1. We cloned these constructs into plasmid pBabe-blast, modified by replacing the puromycin-resistance gene with a blasticidin-resistance gene, to engineer retroviral vectors for derivation of stably transduced clones as described (Vernochet et al., 2009 ). The final concentration of puromycin or blasticidin for selection is 2.5 mg/ml. HA-Pparg (Kitamura et al., 2005) and SirT1 adenoviruses have been described (Nakae et al., 2003) . For transient expression in HEK293T (293) cells, we transfected pcDNA-Pparg or pEGFP-SirT1 using TransIT-LT1 reagent (Mirus Bio), or transduced Pparg or SirT1 adenoviruses. We differentiated and maintained 3T3-L1 preadipocytes, Swiss-3T3 fibroblasts (both from ATCC), and HIB-1B brown preadipocytes as described (Vernochet et al., 2009) . We treated cells overnight with resveratrol (10 mM), troglitazone (10 mM), rosiglitazone (5 mM), nicotinamide (20 mM), or GW9662 (10 mM).
Protein Analysis
We extracted proteins and performed western blotting as described (Qiang et al., 2010) . Sources of antibodies are Dbc1 (Bethyl Laboratories); Ucp1 (Abcam); Adiponectin (Affinity BioReagents); SirT1 and b-catenin (Millipore); Flag M2 and HA (Sigma-Aldrich); Prdm16 (R&D systems); monoclonal or polyclonal acetyl-Lysine, aP2, Perilipin and phospho-CDK substrate (Cell Signaling); actin, tubulin, C/ebpb, Pparg (E8), Pparg (H100), NCoR, and Cox III (Santa Cruz).
Immunoprecipitation and In Vivo Pparg Acetylation
We performed coimmunoprecipitation (coIP) in Flag IP buffer (50 mM Tris [pH 7.9], 150 mM NaCl, 10% glycerol supplemented with protease inhibitors). For immunoprecipitation (IP), we lysed cells into high-salt Flag IP buffer. To detect Pparg acetylation in vivo, we extracted proteins from adipose tissues into highsalt Flag IP buffer and delipidated them by ultracentrifugation (40,000 rpm for 2 hr at 4 C). We incubated lysates with antibody-conjugated agarose beads overnight at 4 C, washed the beads four times and eluted the precipitates by Flag/HA peptides or boiling in nonreducing sample buffer. The antibody-conjugated agarose beads are Flag M2 beads and monoclonal Anti-HA (Sigma-Aldrich), Pparg (H100)-conjugated (Santa Cruz), and antiacetyl-Lysine agarose (ImmuneChem).
Gene Expression Analysis
We isolated RNA with RNeasy Lipid Tissue kit (QIAGEN) and DNase I digestion, synthesized cDNA with High-capacity cDNA Reverse Transcription kit (Applied Biosystems), and performed quantitative real-time PCR (Q-PCR) with goTaq qPCR Master Mix (Promega) in a Bio-Rad CFX96 Real-Time PCR system. We calculated relative gene expression levels by DDCt method using cyclophilin A as internal control. We list primer sequences in Table S1 .
Histology
We used paraffin-embedded sections for H&E, and Ucp1 immunohistochemistry (Abcam, 1:100 dilution). We assessed adipocyte lipid content by Oil red-O staining.
Statistical Analysis
We used unpaired 2-tailed Student's t tests to evaluate statistical significance and p < 0.05 to declare a statistically significant change. We present all values as means ± standard error of means (SEM). 
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